DDInter1175 DDInter927
A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Methotrimeprazine {u} (Compound) resembles {v} (Compound) Moricizine
Methotrimeprazine {u} (Compound) resembles {v} (Compound) Aceprometazine
Methotrimeprazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Methotrimeprazine {u} (Compound) binds {v} (Gene) ADRA1D
Methotrimeprazine {u} (Compound) upregulates {v} (Gene) CNPY3
Methotrimeprazine {u} (Compound) downregulates {v} (Gene) TXNDC9
Methotrimeprazine {u} (Compound) causes {v} (Side Effect) Urinary retention
Methotrimeprazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Methotrimeprazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium carbonate
Methotrimeprazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Methotrimeprazine (Compound) resembles Moricizine (Compound)
Methotrimeprazine (Compound) resembles Aceprometazine (Compound)
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Methotrimeprazine (Compound) binds ADRA1D (Gene)
Methotrimeprazine (Compound) upregulates CNPY3 (Gene)
Methotrimeprazine (Compound) downregulates TXNDC9 (Gene)
Methotrimeprazine (Compound) causes Urinary retention (Side Effect)
Methotrimeprazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Methotrimeprazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate